Fig. 1From: Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutationsKaplan-Meier plots of outcome data by BDX008 classification for the whole cohort (a-b), for patients in subgroups with known BRAF status (c-d), and for patients in subgroups defined by NLR (e-f)Back to article page